Lumbard & Kellner LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,594 shares of the biopharmaceutical company’s stock, valued at approximately $516,000.

Other institutional investors have also modified their holdings of the company. Tudor Investment Corp ET AL increased its position in shares of Gilead Sciences by 81.6% in the first quarter. Tudor Investment Corp ET AL now owns 20,709 shares of the biopharmaceutical company’s stock worth $1,407,000 after buying an additional 9,308 shares during the period. Westover Capital Advisors LLC increased its position in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. Endurant Capital Management LP acquired a new position in shares of Gilead Sciences during the first quarter worth approximately $1,494,000. Shelton Capital Management increased its position in shares of Gilead Sciences by 49.8% in the first quarter. Shelton Capital Management now owns 206,700 shares of the biopharmaceutical company’s stock worth $14,039,000 after buying an additional 68,731 shares during the period. Finally, Sterneck Capital Management LLC increased its position in shares of Gilead Sciences by 75.4% in the first quarter. Sterneck Capital Management LLC now owns 66,932 shares of the biopharmaceutical company’s stock worth $4,546,000 after buying an additional 28,767 shares during the period. 74.06% of the stock is owned by institutional investors.

Shares of Gilead Sciences, Inc. (GILD) traded down 0.41% on Friday, hitting $72.40. 7,029,745 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $72.36 and its 200 day moving average price is $68.77. The stock has a market cap of $94.55 billion, a price-to-earnings ratio of 7.86 and a beta of 1.21. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/13/lumbard-kellner-llc-invests-516000-in-gilead-sciences-inc-nasdaqgild.html.

A number of equities analysts recently commented on the stock. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Friday, July 28th. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Twelve research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $80.31.

In related news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last three months, insiders have sold 206,666 shares of company stock worth $15,223,184. 1.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.